FDA approves once-monthly schizophrenia drug from Durect, Indivior

Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia in adults. The approval triggered a $5 million milestone payment to Durect from Indivior.

The companies said Perseris is the first once-monthly, subcutaneous, long-acting injectable (LAI) containing risperidone to be approved for adults with schizophrenia. According to its label, Perseris is administered as a subcutaneous injection in the abdomen by a healthcare professional...